SCHEMBL2994451

SCHEMBL2994451

Cc1ccc2c(c1)c(C(=O)C(=O)Nc1ccccc1)c(Cl)n2Cc1ccc(Cl)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.48
PLA2G4A P47712 1/20 0.45
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
ALOX12 P18054 2/20 0.41
THRB P10828 1/20 0.41
PPARG P37231 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
EGFR P00533 1/20 0.41
TASP1 Q9H6P5 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4097912 0.94 FAAH (0.51) FAAHPLA2G4ALMNASMN1; SMN2MEN1
SCHEMBL3010526 0.93 FAAH (0.49) FAAHPLA2G4ALMNASMN1; SMN2MEN1
SCHEMBL4384405 0.93 FAAH (0.51) FAAHPLA2G4ALMNASMN1; SMN2MEN1
SCHEMBL2996435 0.93 PLA2G4A (0.46) PLA2G4ALMNASMN1; SMN2MEN1KMT2A
SCHEMBL4384411 0.93 FAAH (0.49) FAAHPLA2G4ALMNASMN1; SMN2MEN1
SCHEMBL3003208 0.91 FAAH (0.53) FAAHPLA2G4ALMNASMN1; SMN2MEN1
SCHEMBL3005762 0.89 MEN1 (0.49) PLA2G4ALMNAMEN1KMT2AALDH1A1
SCHEMBL3006454 0.89 FAAH (0.48) FAAHLMNASMN1; SMN2MEN1KMT2A
SCHEMBL3001563 0.89 ALDH1A1 (0.50) LMNASMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4097877 0.89 FAAH (0.51) FAAHSMN1; SMN2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
EP-2610244-A1 Indole compounds Ironwood Pharmaceuticals, Inc. (US) 2013-07-03 EP disclosed
CN-102850324-A Indole compounds MICROBIA INC 2013-01-02 CN disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 US disclosed
US-20090118503-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197708-A1 INDOLE COMPOUNDS IDO1, IDO2, TPH2 FAAH 109/4885PLA2G4A 1260/4885LMNA 3450/4885
US-20090118503-A1 FAAH INHIBITORS FAAH, FAAH2, CNR2 FAAH 1/4885PLA2G4A 86/4885LMNA 4089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.